Cargando…

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events

Detalles Bibliográficos
Autor principal:	Sullivan, John T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010259/ https://www.ncbi.nlm.nih.gov/pubmed/35303401 http://dx.doi.org/10.1111/cts.13261

Ejemplares similares

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
por: Revet, Alexis, et al.
Publicado: (2020)

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database
por: Jung, Se Yong, et al.
Publicado: (2021)

Pharmacovigilance
por: Griffin, J. P.
Publicado: (1992)

A Sponsor’s View on Postmarketing Regulatory Commitments Involving Human Drug Products
por: McKinley, Laura, et al.
Publicado: (2021)

Postmarket surveillance of high-risk medical devices needs transparent, comprehensive and independent registries
por: Fraser, Alan G
Publicado: (2020)

Workshop on Adverse Drug Reaction Reporting, Pharmacovigilance and Its Implementation in Cancer Hospital in Nepal: An Event Report
por: Shrestha, Sunil, et al.
Publicado: (2020)

Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone
por: Falzon, Dennis, et al.
Publicado: (2014)

Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance
por: Yu, Yihua Bruce, et al.
Publicado: (2023)

Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective
por: Bose, Debdipta, et al.
Publicado: (2021)

Should remdesivir be recommended in France in the early stage of COVID-19
por: Martin, Martinot
Publicado: (2022)

What Do We Know About Remdesivir Drug Interactions?
por: Yang, Katherine
Publicado: (2020)

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
por: Aleissa, Muneerah M., et al.
Publicado: (2020)

Response to "Pharmacovigilance 2030: Invited Commentary for the January 2020 ‘Futures’ Edition"
por: Hauben, Manfred, et al.
Publicado: (2020)

Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
por: Lu, Zhengwu
Publicado: (2009)

The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level
por: Maure, Christine G, et al.
Publicado: (2014)

Pharmacovigilance 2030: Invited Commentary for the January 2020 “Futures” Edition of Clinical Pharmacology and Therapeutics
por: Arlett, Peter, et al.
Publicado: (2019)

Remdesivir: Remedy the world is waiting for?
por: Suranagi, Umesh Devappa, et al.
Publicado: (2020)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

Caution About Truncation-By-Death in Clinical Trial Statistical Analysis: A Lesson from Remdesivir
por: Deng, Yuhao, et al.
Publicado: (2021)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Pharmacovigilance and assessment of drug safety reports during COVID 19
por: Desai, Mira K
Publicado: (2020)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned
por: Dölken, Lars, et al.
Publicado: (2021)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
por: Ali, A. K.
Publicado: (2013)

Pivotal role of Pharmacovigilance Programme of India in containment of antimicrobial resistance in India
por: Agrawal, Vijit, et al.
Publicado: (2019)

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
por: Wu, Bin, et al.
Publicado: (2022)

Effect of CPAP on cardiovascular events in minimally symptomatic OSA: long-term follow-up of the MOSAIC randomised controlled trial
por: Tang, Ivan, et al.
Publicado: (2020)

Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
por: Thota, Prasad, et al.
Publicado: (2018)

Cardiac Adverse Events With Remdesivir in COVID-19 Infection
por: Gupta, Anupam K, et al.
Publicado: (2020)

Can changing the prodrug moiety in remdesivir be a life-saving strategy in COVID-19 infection?
por: Prabha, Praisy K., et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database
por: Thai-Van, Hung, et al.
Publicado: (2023)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan
por: Okubo, TK, et al.
Publicado: (2017)

PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System
por: Ivos, R., et al.
Publicado: (2021)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_go2q0n9ra16r1jj20bgogu99a3